The World of Health & Medicine News

 HIV pill improves diabetic eye disease without injections

 HIV pill improves diabetic eye disease without injections

An inexpensive pill for treating HIV could become an alternative to injections for diabetic eye disease, a small study suggests.

“An oral drug that improves vision in diabetic macular edema (DME) would be a game changer because it would be more convenient for patients than frequent, often monthly, injections into the eye,” study leader Dr. Jayakrishna Ambati of the University of Virginia said in a statement.

At the start of the study, 24 patients in Brazil with DME were randomly assigned to receive Viiv Healthcare’s oral antiviral drug Epivir (lamivudine) or a placebo for four weeks, to be followed by a standard injection of Roche’s (ROG.S), opens new tab Avastin (bevacizumab) into the clear gel-like area that fills the eye between the lens and retina.

After that initial four weeks, the ability to read letters on an eye chart had improved by 9.8 letters, or about 2 lines on the eye chart, in the lamivudine group, while it had decreased by 1.8 letters in the placebo group.

Four weeks after the Avastin injection, the lamivudine recipients had improved by 16.9 letters, more than 3 lines on the chart, while the group that got just Avastin improved by only 5.3 letters.

The HIV drug inhibits an early step in the inflammatory process that leads to DME, the researchers explained in a report published on Tuesday in the Cell Press journal Med, opens new tab.

That mechanism of action is different from existing treatments, “so we could also develop combination therapies,” Ambati said.

While the results suggest that lamivudine may work both with and without Avastin injections, the Viiv drug alone could be life changing for patients in regions with limited access to specialty doctors or who are unable to afford or travel to monthly eye appointments, Ambati said.

“A $20-a-month or even cheaper oral pill that improves vision as much as or more than therapy with injections into the eye that cost up to $2,000 per month could be transformative both for patients and the healthcare system,” Ambati said.

spot_img

Explore more

spot_img

GSK, Spero stop UTI drug trial after early success

GSK, Spero stop UTI drug trial after early success GSK plans to seek approval of a new antibiotic for complicated urinary tract infections after...

New robot helps old people with frailty to walk without fear...

New robot helps old people with frailty to walk without fear of falls Getting on in years means not being as light on one's feet...

Pfizer-Arvinas breast cancer drug tops AstraZeneca’s in delaying progression

Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression An experimental treatment by Pfizer (PFE.N), opens new tab and Arvinas (ARVN.O), opens new tab delayed progression of breast cancer...

China approves first domestically produced nine-valent HPV vaccine

China approves first domestically produced nine-valent HPV vaccine China approved its first domestically developed nine-valent human papillomavirus (HPV) vaccine on Thursday, according to the National...

5 ways smoking causes damage beyond lungs and heart, and issues...

5 ways smoking causes damage beyond lungs and heart, and issues from herpes to infertility Are you a smoker – or does someone you love...

Amgen blood platelet booster helps patients who need chemotherapy

Amgen blood platelet booster helps patients who need chemotherapy Ahead of the American Society of Clinical Oncology (ASCO) meeting, researchers reported that Amgen’s Nplate, a...

Gilead’s Trodelvy, with Keytruda, cuts breast cancer risk by 35% in...

Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial Gilead Sciences' (GILD.O), opens new tab Trodelvy in combination with Merck's (MRK.N), opens new tab blockbuster immunotherapy...

Gilead commits to HIV prevention rollout for low-income countries despite funding...

Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty Gilead Sciences says it still plans to supply its twice-yearly injection for preventing...